Advertisement

Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 600x60px
Document › Details

Epigenomics AG. (11/7/11). "Press Release: Open Letter to the Editor of »Clinical Gastroenterology and Hepatology« Regarding a Recently Published Article in that Journal".

Region Region United States (USA)
Organisations Organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
  Organisation 2 ARUP Laboratories
  Group University of Utah
Products Product SEPT9 DNA Methylation Biomarker (mSEPT9)
  Product 2 colorectal cancer test, early detection (Epigenomics)
Person Person Beck, Jürgen (Promethera 201512– VP Clinical + Medical Affairs before Boehringer + Synthélabo + Epigenomics + InterMune)
     


Open Letter to the Editor

C. Mel Wilcox, MD, Editor,
Clinical Gastroenterology and Hepatology,
AGA, 4930 Del Ray Avenue, Bethesda, Maryland 20814-3015;
e-mail: cgh@gastro.org;


Referring to: The Stool DNA Test is More Accurate than the Plasma Septin 9 Test in Detecting Colorectal Neoplasia. Clin Gastroenterol Hepatol. 2011 Oct 19. Author(s): Ahlquist DA, Taylor WR, Mahoney DW, Zou H, Domanico M, Thibodeau SN, Boardman LA, Berger BM, Lidgard GP. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester MN.

Sir,

In the referenced article, a plasma-test for methylated Septin9 is compared to a stool DNA test, with results inconsistent with those previously reported for the ARUP Septin9 LDT . We developed and licensed the Septin9 technology to ARUP Laboratories and the results reported in the article are inconsistent with our experience of the Septin9 biomarker as well. Careful review of study methodology indicates systemic flaws in the reporting, including missing information and incomplete authorship with a bias potentially originating from the first author's financial interest in the success of the stool DNA test.

An explanation of the selection process for CRC cases tested in the study is lacking and is described as "selected if they had participated in a recent multicenter evaluation of a prototype next generation sDNA test". A selection process rather than a more unbiased design of testing all subjects with both tests indicates that bias could have been introduced particularly if a inordinate number of sDNA test positive subjects were chosen. The use of a different set of colonoscopy normal control patients for each test makes any comparison illusive. The choice of the controls for the blood test seems to be inadequate, with both the unusually high false positive rate and the occurrence of 8% (4/49) other cancers in the plasma control group casting doubt whether they represent average risk individuals.

The study employed archived samples although little information is provided on sampling procedures, blood collection tubes used or timing of blood collection - all of which have a significant impact on Septin9 performance. The authors conceded that plasma sample preparation was only "similar" to the test commercialized by ARUP Laboratories. An accurate comparison can only be achieved when both tests have been performed according to procedures that would occur in routine clinical practice. Finally, it seems telling that no co-author from ARUP has been involved in manuscript preparation. This incomplete authorship further supports the grave concern that the article presents a methodologically flawed and biased study. We have knowledge of a letter dated April 15th, 2011 and addressed by ARUP to the first author objecting to a publication. In this letter, an ARUP co-investigator of the study formally raised concerns on the validity of the data.

In summary, the lack of complete protocol information, the lack of a shared set of colonoscopy-normal controls, the nebulous clinical history of the plasma control patients and the incomplete study authorship casts serious doubts about this study as a sincere, scientific comparison between Dr Ahlquist's stool DNA test and a Septin9 plasma test.

Sincerely yours,


Dr. med. Jürgen Beck Shannon Payne, Ph.D
Senior Vice President Medical Affairs Medical Science Liaison

Epigenomics AG | Kleine Praesidentenstr. 1 | 10178 Berlin, Germany and Epigenomics, Inc. | 901 Fifth Ave, Ste 3800 | Seattle, WA 98164-2044, USA


   
Record changed: 2016-06-15

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for Epigenomics (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wptb




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 Barcelona 120x240px wpssy Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px